¡¡¡¡On May 5, 2017, the US Food and Drug Administration (FDA) announced that it had approved a drug called Radicava (edaravone) for the treatment of amyotrophic lateral sclerosis (ALS), the first drug of its kind to be approved by the FDA in over 20 years. This drug is developed by Mitsubishi Pharmaceutical Co., Ltd. in Tanabe, Japan.
¡¡¡¡ALS, also known as ALS, is a rare progressive neurodegenerative disease. The motor nerve cells in the patient's brain, brainstem, and spinal cord are invaded, and the muscles gradually atrophy and become weak, leading to paralysis. At the same time, it is accompanied by symptoms such as decreased speech, swallowing, and respiratory function, gradual atrophy and paralysis, and the body feels like it is gradually frozen, hence it is called a "gradually frozen person".